

Setting the standard

Thermo Scientific™ ImmunoCAP™ Specific IgE

Stinging Insect Allergen Components*

Use this guide to interpret ImmunoCAP allergen component test results and unlock a broader understanding of a patient's allergic sensitization, allowing for a more comprehensive management plan.¹

**Up to
50%**

of venom allergic patients test positive for both bee and wasp venom because of cross-reactivity.²
Component resolved IgE tests using recombinant venom allergens may improve specificity³—increasing the likelihood of successful venom immunotherapy.⁴

Testing with stinging insect components can help to:¹⁻⁹

 Identify species specific sensitization and/or cross-reactivity⁴

 Identify culprit venom(s)⁵

 Facilitate accurate prescription of venom immunotherapy (VIT)⁵

Stinging Insect Profile

Hymenoptera venom allergy profiles may consist of five whole allergens, eight components, Tryptase and CCD-Bromelain (MUXF3).⁶

i1. Honeybee

i3. Common Wasp (Yellow Jacket)

i4. Paper Wasp

i2. White Faced Hornet[†]

i5. Yellow Hornet[†]

Honeybee
Apis mellifera



Yellow Jacket
Vespa vulgaris



Paper Wasp
Polistes dominula



Differentiating marker allergen

Api m 1 Phospholipase A2

Api m 3 Acid phosphatase

Api m 10 Icarapin

Ves v 1 Phospholipase A1

Ves v 5 Antigen 5

Pol d 5 Antigen 5

Cross-reactive allergens

Api m 2 Hyaluronidase


Api m 5 Dipeptidyl peptidase

Adapted from S. Blank, M. B. Bilo, M. Ollert Component-resolved diagnostics to direct in venom immunotherapy: Important steps towards precision medicine Clin Exp Allergy. 2018;48:p357. 2018

Management Considerations⁶⁻⁸

Results should be interpreted in the context of a patient's clinical symptoms and history.

CCD-Bromelain (MUXF3) should be measured to assess cross-reactivity between species.⁹



Tryptase should be analyzed in patients with a history of a severe sting reaction and before starting venom VIT.^{3,10-14}

EAACI, AAAAI, WAO, ICON

ImmunoCAP™ Tryptase is FDA cleared for in vitro diagnostic use as an aid in the clinical diagnosis of patients with a suspicion of systemic mastocytosis in conjunction with other clinical findings.

Whole allergens can be made up of numerous components. A positive whole allergen sensitization with negative component sensitization may mean a patient is sensitized to a component that is not yet available for testing. Consider a patient's clinical history, cross-reactivity between species, and referral to specialist.

*Official product names of allergen components mentioned within this document: ImmunoCAP Allergen i1, Honey bee venom; ImmunoCAP Allergen i208, Allergen Component rApi m 1; ImmunoCAP Allergen i214, Allergen Component rApi m 2; ImmunoCAP Allergen i215, Allergen Component rApi m 3; ImmunoCAP Allergen i216, Allergen Component rApi m 5; ImmunoCAP Allergen i217, Allergen Component rApi m 10; ImmunoCAP Allergen i4, Paper wasp; ImmunoCAP Allergen i210, Allergen Component rPol d 5, European Paper wasp; ImmunoCAP Allergen i3, Common wasp venom (Yellow jacket); ImmunoCAP Allergen i211, Allergen Component rVes v 1, Common wasp; ImmunoCAP Allergen i209, Allergen Component rVes v 5, Common wasp; ImmunoCAP Allergen i5, Yellow hornet venom; ImmunoCAP Allergen i2, White-faced hornet venom

References

1. Kleine-Tebbe J, Jappe U. Molecular allergy diagnostic tests: development and relevance in clinical practice. *Allergologie select*. 2017;1 (2):169-189.
2. Spillner E, et al., Hymenoptera allergens: from venom to "venome". *Frontiers in immunology* 2014; 5: 1-7.
3. Golden, et.al Stinging insect hypersensitivity A practice parameter update 2016 *Ann Allergy Asthma Immunol* 118 (2017) p28-54
4. Matricardi PM, et al EAACI Molecular Allergology User's Guide. *Pediatr Allergy Immunol* 2016; 27: (suppl23): p157. 2016
5. Silke C. Hofmann, MD , et al Added value of IgE detection to rApi m 1 and rVes v 5 in patients with Hymenoptera venom allergy *J ALLERGY CLIN IMMUNOL VOLUME* 127, NUMBER 1 265-267 2010
6. Ansotegui I. A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMDI®): Update 2020. *World Allergy Organization Journal*. 2020;13(2):100091.
7. S. Blank, M. B. Bilo, M. Ollert Component-resolved diagnostics to direct in venom immunotherapy: Important steps towards precision medicine *Clin Exp Allergy*. 2018;48:p357. 2018
8. Barber D, Diaz-Perales A, Escrivére M, Kleine-Tebbe J, Matricardi P, Ollert M, Santos A, Sastre J. Molecular allergology and its impact in specific allergy diagnosis and therapy. *Allergy*. 2021;76(12):3642-3658.
9. Irene Mittermann, PhD, Mihaela Zidarn, MD, Mira Silar, P7HD, Zora Markovic-Housley, PhD, Werner Aberer, MD, Peter Korosec, PhD, Mitja Kosrik, PhD, MD, and Rudolf Valenta, MD. Recombinant allergen- based IgE testing to distinguish bee and wasp allergy. *J ALLERGY CLIN IMMUNOL VOLUME* 125, NUMBER 6 p1300-1307. 2010
10. Bonifazi F, et al & EAACI Interest Group on Insect Venom Hypersensitivity. Diagnosis of Hymenoptera venom allergy. *Allergy* 2005; 60: 1459-1470.
11. Bil B, et al & EAACI Interest Group on Insect Venom Hypersensitivity. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. *Allergy* 2005; 60: 1459-1470.
12. Simons FE, et al, International concensus on (ICON) anaphylaxis. *World Allergy Organ J*. 2014 May 30;7(1):9.
13. Simons FE, et al., World Allergy Organization Anaphylaxis Guidelines:2013 update of the evidence base. *Int Arch Allergy Immunol*.2013;162(3):193-204.
14. Cox L, et al., Allergen Immunotherapy: A practice parameter third update. *J Allergy Clin Immunol* 2011;127(1):s1-s5.

Learn more at thermofisher.com/allergencomponents

© 2022 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. 149004.AL.US1.EN.v1.22